INS and diabetes mellitus: Therefore, GLP−1 agonists can be used as a drug in diabetes treatment by mimicking the hormone GLP−1 and binding to GLP−1 receptors on beta cells, which stimulates glucose-dependent insulin secretion from pancreatic islets, leading to a reduction in blood glucose levels.